Wave Life Sciences (DB:1U5) - Hisse Senedi Fiyatı, Haberler ve Analizler

1U5 Stoklara Genel Bakış

1U5 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 42.36% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Wave Life Sciences Ltd. Rakipler

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€287.8m

Bayer

XTRA:BAYN

€19.6b

MPH Health Care

DB:93M1

€105.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Wave Life Sciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$13.60
52 Haftanın En Yüksek Seviyesi	US$15.70
52 Haftanın En Düşük Seviyesi	US$3.28
Beta	-1.21
11 Aylık Değişim	-0.73%
3 Aylık Değişim	164.08%
1 Yıllık Değişim	184.52%
33 Yıllık Değişim	306.94%
5 Yıllık Değişim	-54.05%
Halka arzdan bu yana değişim	-61.70%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	1U5	DE Pharmaceuticals	DE Pazar
7D	7.1%	1.4%	0.8%
1Y	184.5%	-18.4%	9.1%

Getiri vs. Endüstri: 1U5 geçen yıl % -18.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: 1U5 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 1U5's price volatile compared to industry and market?
1U5 volatility
1U5 Average Weekly Movement	25.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 1U5 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 1U5 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 16% dan 26% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	267	Paul B. Bolno	www.wavelifesciences.com

Klinik aşamada bir biyoteknoloji şirketi olan Wave Life Sciences Ltd. bir keşif ve ilaç geliştirme platformu olan PRISM aracılığıyla ribonükleik asit (RNA) ilaçları tasarlamakta, geliştirmekte ve ticarileştirmektedir. Şirketin RNA ilaçları platformu PRISM, hem nadir hem de yaygın bozuklukları tedavi eden bilimsel atılımlar sunmak için çoklu modaliteleri, kimya inovasyonunu ve insan genetiğine ilişkin derin içgörüleri birleştirmektedir.

Wave Life Sciences Ltd. Temel Bilgiler Özeti

Wave Life Sciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1U5 temel i̇stati̇sti̇kler
Piyasa değeri	€2.07b
Kazançlar(TTM)	-€135.79m
Gelir(TTM)	€51.08m

42.4x

P/S Oranı

-15.9x

F/K Oranı

1U5 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1U5 gelir tablosu (TTM)
Gelir	US$53.61m
Gelir Maliyeti	US$149.11m
Brüt Kâr	-US$95.50m
Diğer Giderler	US$47.02m
Kazançlar	-US$142.52m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.93
Brüt Marj	-178.14%
Net Kâr Marjı	-265.84%
Borç/Özkaynak Oranı	0%

1U5 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

1U5 Stoklara Genel Bakış

Ödüller

Risk Analizi

Wave Life Sciences Ltd. Rakipler

XTRA:DMP

€2.0b

XTRA:PSG

€287.8m

XTRA:BAYN

€19.6b

DB:93M1

€105.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.066 profit in 3Q 2023)

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $250 million.

Wave Life Sciences Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Wave Life Sciences Ltd. Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

New major risk - Shareholder dilution

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200.000004 million.

Recent updates

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.066 profit in 3Q 2023)

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $250 million.

Wave Life Sciences Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Wave Life Sciences Ltd. Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

New major risk - Shareholder dilution

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200.000004 million.

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $131.97401 million.

Wave Life Sciences Ltd. Announces Positive Interim Data from Forward-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.20 loss in 2Q 2023)

Wave Life Sciences Ltd. Announces Positive Results from Phase 1b/2a Select-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 06, 2024

New major risk - Revenue and earnings growth

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Wave Life Sciences Ltd. to Report Q1, 2024 Results on May 09, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.05 loss in FY 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.62 loss in 2Q 2022)

Wave Life Sciences Ltd. to Report Q2, 2023 Results on Aug 03, 2023

Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

President recently sold €111k worth of stock

Wave Life Sciences Provides Positive Update on Proof-Of-Concept Study for Wve-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Insufficient new directors

Insufficient new directors

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 09, 2022

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from Russell 2000 Dynamic Index

Wave Life Sciences Ltd. Announces First Clinical Data from Ongoing Focus-C9 Trial of Wve-004 for C9-Als and C9-Ftd

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Wave Life Sciences Ltd. Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

President recently sold €68k worth of stock

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.86 loss in 3Q 2020)

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

First half 2021 earnings released: US$1.65 loss per share (vs US$2.53 loss in 1H 2020)

Wave Life Sciences Ltd. Announces Proof-of-Concept Preclinical Data for Adar Editing Program in Alpha-1 Antitrypsin Deficiency

Full year 2020 earnings released: US$3.82 loss per share (vs US$5.72 loss in FY 2019)

Revenue misses expectations

New 90-day high: €8.35

Wave Life Sciences Ltd. Announces Key Upcoming Milestones for 2021 and Continued Advancement of Proprietary Discovery and Drug Development Platform